# Intent To Grant an Exclusive License of a U.S. Government-Owned Patent
**AGENCY:**
Department of the Army, DoD.
**ACTION:**
Notice.
**SUMMARY:**
In accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(I)(i), announcement is made of the intent to grant an exclusive, royalty-bearing, revocable license to U.S. Patent 6,825,323, filed January 10, 2001, entitled “Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using the same” and foreign rights (PCT/US01/000725) to ProFibrix B.V., with its principal place of business at Zernikedreef 9, 2333 CK Leiden, The Netherlands.
**ADDRESSES:**
Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-ZA-J, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.
**FOR FURTHER INFORMATION CONTACT:**
For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664. For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808, both at telefax (301) 619-5034.
**SUPPLEMENTARY INFORMATION:**
Anyone wishing to object to the grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Command Judge Advocate (see *ADDRESSES* ).
Brenda S. Bowen,
Army Federal Register Liaison Officer.